The 2016 Annual Report for Abbott Laboratories covers their strategic and financial performance. Key highlights include strategic acquisitions, such as St. Jude Medical, enhancing their cardiovascular market presence, and divesting Abbott Medical Optics to Johnson & Johnson. These actions align with Abbott’s focus on growth areas in healthcare. The annual report also indicates global sales growth and consistent dividend increases, reflecting financial stability. Abbott’s strategy emphasizes diversifying its portfolio across various healthcare segments and geographical markets, prioritizing long-term growth potential. Overall, the report illustrates Abbott’s aim to be a leader in healthcare through innovation and market presence.
Business Restructuring: Abbott has focused on reshaping itself to accelerate growth, including acquiring St. Jude Medical and divesting its vision care business, Abbott Medical Optics.
Financial Performance: Abbott reported total sales of $20.85 billion in 2016, with a net earnings of $1.4 billion. They achieved global sales growth of 2.2% and a dividend increase for the 45th consecutive year.
These figures indicate Abbott’s financial stability and growth in the healthcare sector.
Strategic Focus: The report emphasizes Abbott’s strategic decisions to strengthen its position in large and growing markets, particularly in cardiovascular care and medical devices.
Innovation and Leadership: Abbott highlights its innovation in products like the FreeStyle Libre glucose-monitoring system and Absorb bioresorbable stent, underlining its leadership in healthcare solutions.
Global Presence: The company’s presence in emerging markets is emphasized, with a focus on branded generics and a diversified portfolio across medical devices, diagnostics, nutrition, and pharmaceuticals.
Access the full report here:
